DIA/FDA Oligonucleotide-based Therapeutics 2012: Leveraging Regulators and Industry Knowledge for Future Advancements

Join Industry and Global Regulatory Representatives to Discuss Advances in Oligonucleotide Science

For the past four years DIA/FDA has convened industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development. The 2012 event will continue to address bioinformatics, microRNAs, delivery methods, impurity issues, metabolism, non-clinical assessments in support of drug development and clinical advances in therapeutic targets, trial design and safety. This conference will also incorporate dialogue to address RNA interference technologies and expand clinical pharmacology representation in discussions of the emerging technologies being developed in the field of oligonucleotide-based therapeutics.